Related Experiment Videos
HLA expression in cancer: implications for T cell-based immunotherapy.
Immunogenetics
|August 9, 2001
Summary
Human Leukocyte Antigen (HLA) class I expression is altered in many tumors, with most tumors retaining expression. These findings support the development of immunotherapies targeting HLA class I.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Human Leukocyte Antigen (HLA) class I expression is crucial for immune surveillance.
- Alterations in HLA class I expression are observed in various cancers.
- Understanding these alterations is key for developing effective cancer immunotherapies.
Purpose of the Study:
- To review the status of HLA class I expression across different tumor types.
- To assess the implications of HLA class I alterations for cancer immunotherapy.
Main Methods:
- Review of existing literature and data on HLA class I expression in tumors.
- Analysis of immunohistochemical data and pathological changes.
Main Results:
- HLA class I expression is altered in a significant fraction of tumor types.
- A majority of tumors analyzed express HLA class I.
- More severe alterations in HLA class I expression correlate with later-stage and less differentiated tumors.
Conclusions:
- The prevalence of HLA class I expression in tumors is encouraging for immunotherapy development.
- Potential for immunotherapy is supported by the possibility of inducing HLA expression and the sensitivity of HLA-negative cells to natural killer cell lysis.